Australia\'s Boral urges shareholders to reject Seven Group\'s $1.3 billion offer

By Scott Murdoch and Roushni Nair (Reuters) -Australia\'s Boral (OTC:BOALY) on Tuesday recommended investors reject its largest shareholder Seven Group Holdings\' A$1.9 billion ($1.25 billion) offer for the company claiming it undervalues the building products group. Seven Group, controlled by billionaire Kerry Stokes and his family, already owns nearly 72% of Boral and had launched...

Read More

Macquarie and Canada\'s PSP start AirTrunk data centre sales process, source says

By Scott Murdoch SYDNEY (Reuters) - Australia\'s Macquarie Group (OTC:MQBKY) and Canada\'s Public Sector Pension Investment Board are starting a sales process for their AirTrunk data centre business, according to a source with direct knowledge of the matter. The pair sent non-disclosure agreements on Tuesday to potential buyers to sign ahead of a formal transaction...

Read More

Madrigal Pharmaceuticals upsizes public offering to $600 million

CONSHOHOCKEN, Pa. - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a company specializing in treatments for nonalcoholic steatohepatitis (NASH), has upsized its public offering to $600 million, the firm announced Monday. The offering, originally set at $500 million, was increased by $100 million following strong investor interest. The company is offering 750,000 shares of common stock at $260...

Read More

Baird starts Axsome Therapeutics stock at Outperform on promising trial outlook

Tuesday, Baird initiated coverage on shares of Axsome Therapeutics (NASDAQ:AXSM), assigning the stock an Outperform rating and setting a price target of $108.00. The firm has expressed confidence in the company\'s upcoming clinical trial results, particularly for its AXS-05 drug, which is currently in phase 3 trials for Alzheimer\'s disease agitation, expected in the second...

Read More